UNSPSC 51171636: Danthron or dantron

This classification denotes a carcinogenic anthraquinone with the molecular formula C14H8O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z4XE6IBF3V, chemically known as 1,4,5,8-tetroxyantraquinone but generally known as danthron, which bears US NIH Compound Identifier 2950. European Medicines Agency schedules Danthron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06904MIG.

The term DANTRON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). World Health Organization schedules danthron in its Anatomical Therapeutic Chemical (ATC) Classification. Danthron or dantron bears US NLM identifiers UMLS ID C0057135 and NCI Concept Code C44363. SMILES: O=C1C2C(C(=O)C3C1C(O)CCC3)CCCC2O.

UNSPSC 51171636 Danthron or dantron is a Commodity code that captures pharmaceutical active ingredients and formulated drug products procured by state and local health, correctional, and benefits administration agencies. Recent opportunities under this code show state and local governments buying drug testing services, pharmacy benefit management, and pharmaceutical distribution through cooperative purchasing vehicles. The issuing bodies span state health and human services commissions, county correctional departments, and multistate cooperative purchasing alliances. Work solicited includes offender drug screening and confirmation testing, direct-to-manufacturer prescription programs, and generic pharmaceutical distribution through authorized wholesalers.

Activity appears concentrated in Texas and Minnesota, with the most substantial recent opportunity posted by Collin County Community Supervision and Corrections Department on July 9, 2026 (RFP 2026-327, response due July 23, 2026) seeking offender specimen collection and drug testing services for approximately 25,031 annual tests at an estimated contract value of $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026 (S1070000015802, response due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products distributed to Minnesota and Oregon state and local facilities through three authorized wholesalers. MMCAP contracts run two years for new responders with optional extensions; pricing is weighted at 75 percent of the evaluation score.